Evidence map›Paper›PMID 40723377›Full record

ArticleBiology2025

DIRAS1 Drives Oxaliplatin Resistance in Colorectal Cancer via PHB1-Mediated Mitochondrial Homeostasis.

Min Long, Qian Ouyang, Jingyi Wen, Xuan Zeng, Zihui Xu, Shangwei Zhong, Changhao Huang, Jun-Li Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Min LongThe Cancer Research Institute, Hengyang Medical School, University of South China (USC), Hengyang 421001, China.
Qian OuyangThe Cancer Research Institute, Hengyang Medical School, University of South China (USC), Hengyang 421001, China.
Jingyi WenThe Cancer Research Institute, Hengyang Medical School, University of South China (USC), Hengyang 421001, China.
Xuan ZengThe Cancer Research Institute, Hengyang Medical School, University of South China (USC), Hengyang 421001, China.
Zihui XuThe Cancer Research Institute, Hengyang Medical School, University of South China (USC), Hengyang 421001, China.
Shangwei ZhongThe Cancer Research Institute, Hengyang Medical School, University of South China (USC), Hengyang 421001, China.
Changhao HuangDepartment of Organ Transplantation, Xiangya Hospital, Central South University, Changsha 410008, China.
Jun-Li LuoThe Cancer Research Institute, Hengyang Medical School, University of South China (USC), Hengyang 421001, China.ORCID 0000-0002-7625-4766

Funding

National Natural Science Foundation of China Nos. 81974469 ， 82472835，82203166 and82302972
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is a prevalent global malignancy with particularly challenging treatment outcomes in advanced stages. Oxaliplatin (OXA) is a frontline chemotherapeutic agent for CRC. However, 15% to 50% of stage III patients experience recurrence due to drug resistance. Elucidating the molecular mechanisms underlying OXA resistance is, therefore, crucial for improving CRC prognosis. The role of DIRAS1, a RAS superfamily member with reported tumor-suppressive functions in various cancers, remains poorly defined in CRC.

methodsThe effects of DIRAS1 on CRC cell proliferation and migration were evaluated using MTT, wound healing, and colony formation assays. Stable cell lines with knockdown or overexpression of DIRAS1 and PHB1 were established via plasmid and lentiviral systems. Drug sensitivity to OXA was assessed through cytotoxicity assays and IC

resultsDIRAS1 expression was positively correlated with OXA resistance and was significantly upregulated following prolonged chemotherapy exposure. Silencing DIRAS1 reduced the IC

conclusionsThis study identifies DIRAS1 as a key contributor to OXA resistance in CRC by modulating PHB1 expression and mitochondrial function. Targeting the DIRAS1-PHB1 axis may offer a novel therapeutic strategy to overcome chemoresistance in CRC.

Indexed as

colorectal cancerDIRAS1mitochondrial functionoxaliplatin resistancePHB1targeted therapy

Identifiers

PMID40723377
PMCPMC12292402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.